Credit Suisse’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Credit Suisse’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-33,777	Closed	-$931K	–	4660
2021 Q2	$931K	Sell	33,777 -8,979	-21%	-$176K	﹤0.01%	3444
2021 Q1	$705K	Sell	42,756 -49,868	-54%	-$1.14M	﹤0.01%	3547
2020 Q4	$1.71M	Sell	92,624 -93,593	-50%	-$1.68M	﹤0.01%	2941
2020 Q3	$2.54M	Buy	186,217 +133,865	+256%	+$2.06M	﹤0.01%	2250
2020 Q2	$939K	Buy	+52,352	New	+$789K	﹤0.01%	2946

Credit Suisse's TBIO Position: Q3 2021 in Review

Credit Suisse sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 33,777 shares — an estimated $931K sold.

Credit Suisse first reported a position in TBIO in Q2 2020 and held it in 5 quarters. The position peaked at $2.54M in Q3 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Credit Suisse reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Credit Suisse sold 33,777 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $931K.
Credit Suisse first reported a position in Translate Bio, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Credit Suisse's Translate Bio, Inc. Common Stock position peaked at $2.54M in Q3 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Credit Suisse's 13F filing for Q3 2021, filed 12 Nov 2021.